#60040

## KIR2DL3 (D8L3D) Rabbit mAb



Orders:	877-616-CELL (2355 orders@cellsignal.com
Support:	877-678-TECH (8324
Web:	info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: FC-L	Reactivity: H	Sensitivity: Endogenous	<b>MW (kDa):</b> 60	Source/Isotype: Rabbit IgG	UniProt ID: #P43628	Entrez-Gene Id: 3804	
Product Usage Information		<b>Application</b> Flow Cytometry (Live)			<b>Dilution</b> 1:100		
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.					
Specificity/Sens	itivity	KIR2DL3 (D8L3D) Rabbit mAb recognizes endogenous levels of total KIR2DL3 protein. This antibody weakly cross-reacts with KIR2DL2 proteins in over-expression cell lines.					
Source / Purifica	ation	Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala173 of human KIR2DL3 protein.					
Background		Killer cell immunoglob natural killer (NK) cells human leukocyte antig of the KIR gene cluster haplotypes (6,7). The k superfamily domains ( 10). KIR proteins with f an immune tyrosine-b domain lack an ITIM a role in the regulation of susceptibility to autoir transplantation (12-14	ulin-like receptors and subsets of CD gen class I (HLA cla r varies among hap (IR proteins are cha 2D or 3D) and by w the long cytoplasm ased inhibitory mo nd instead transdu of the immune resp nmunity and infect ).	(KIRs) are type 1 transm 4, CD8, and γδ T cells (1- ss I) ligands, the KIR gen lotypes, although severa aracterized by the number whether they have a long ic domain transduce inh tif (ITIM) (10), while KIR p ce activating signals (11, sonse. Combinations of b ious disease, as well as c	embrane glycoprot 5). Analogous to th es are polymorphic al "framework" gen er of extracellular ir (L) or short (S) cyto ibitory signals upor oroteins with the sh 12). KIR proteins pl (IR and HLA class I outcomes of haema	eins expressed by e diversity of their : and the content es are found in all nmunoglobulin- plasmic domain (8- n ligand binding via iort cytoplasmic ay an important variants influence itopoietic stem cell	
		KIR2DL3, also referred to as CD158b, interacts with HLA-C alleles (HLA-Cw1, HLA-Cw3, and HLA-Cw7). Upon receptor ligand interaction, KIR2DL3 inhibits the activity of NK cells thus preventing target cell lysis (15-17).					
Background Re	ferences	<ol> <li>Young, N.T. et al. (20</li> <li>Battistini, L. et al. (11</li> <li>Björkström, N.K. et al.</li> <li>Remtoula, N. et al. (15</li> <li>Béziat, V. et al. (2017</li> <li>Uhrberg, M. et al. (17</li> <li>Shilling, H.G. et al. (2001</li> <li>Boyington, J.C. et al.</li> <li>Yoivian, J.P. et al. (2001</li> <li>Boyington, J.C. et al.</li> <li>Vivian, J.P. et al. (2011</li> <li>Stewart, C.A. et al.</li> <li>Ivarsson, M.A. et al.</li> <li>Kulkarni, S. et al. (2012</li> <li>Kulkarni, M.P. and Cats.</li> <li>Colonna, M. et al. (16. Winter, C.C. et al.)</li> <li>Moesta, A.K. et al.</li> </ol>	01) <i>J Immunol</i> 166, 997) <i>J Immunol</i> 159 al. (2012) <i>Blood</i> 120 2008) <i>J Immunol</i> 18 7) <i>Immunology</i> 150 997) <i>Immunity</i> 7, 7 2002) <i>J Immunol</i> 2, 4 (2000) <i>Nature</i> 405, 111) <i>Nature</i> 479, 40 (2005) <i>Proc Natl Ac</i> 1008) <i>Semin Immun</i> arrington, M. (2013) 1993) <i>Proc Natl Ac</i> 998) <i>J Immunol</i> 16 (2008) <i>J Immunol</i> 16	. 3933-41. , 3723-30. ), 3455-65. 10, 2767-71. , 248-264. 53-63. 8, 2307-15. 52-60. 537-43. 1-5. <i>vad Sci USA</i> 102, 13224-9. <i>unol</i> 5, 184. <i>vol</i> 20, 343-52. ) <i>Immunol Rev</i> 254, 245- <i>vad Sci U S A</i> 90, 12000-4. 1, 571-7. 80, 3969-79.	64.		
Species Reactiv	ity	Species reactivity is de	termined by testin	g in at least one approve	d application (e.g.,	western blot).	
Applications Ke	у	FC-L: Flow Cytometry (	Live)				
Cross-Reactivity	/ Key	H: Human					

Trademarks and Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.			
	Alexa Fluor is a registered trademark of Life Technologies Corporation.			
	All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.			
Limited Uses	Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.			
	Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.			